Equities analysts forecast that Spark Therapeutics Inc (NASDAQ:ONCE) will announce earnings of ($1.74) per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Spark Therapeutics’ earnings, with estimates ranging from ($2.00) to ($1.38). Spark Therapeutics reported earnings of ($1.22) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 42.6%. The firm is expected to report its next quarterly earnings report on Wednesday, February 28th.

On average, analysts expect that Spark Therapeutics will report full-year earnings of ($7.62) per share for the current financial year, with EPS estimates ranging from ($8.08) to ($7.20). For the next fiscal year, analysts anticipate that the company will post earnings of ($5.83) per share, with EPS estimates ranging from ($6.99) to ($4.61). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. During the same quarter last year, the firm earned ($1.07) EPS. The company’s revenue was up 45.8% on a year-over-year basis.

Several research analysts have commented on the stock. UBS cut shares of Spark Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $92.00 to $51.00 in a report on Tuesday. BMO Capital Markets set a $73.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday. SunTrust Banks set a $101.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, October 16th. Chardan Capital lowered their price target on shares of Spark Therapeutics from $100.00 to $60.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Sanford C. Bernstein set a $71.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $76.19.

Spark Therapeutics (NASDAQ:ONCE) traded down $0.70 during midday trading on Friday, reaching $45.21. 1,524,400 shares of the company’s stock traded hands, compared to its average volume of 485,468. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.

In related news, insider Barge Joseph La sold 3,309 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $71.31, for a total value of $235,964.79. Following the completion of the sale, the insider now owns 8,146 shares in the company, valued at approximately $580,891.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Daniel Faga sold 1,500 shares of the company’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the completion of the sale, the insider now owns 1,500 shares of the company’s stock, valued at approximately $127,500. The disclosure for this sale can be found here. Insiders have sold a total of 1,068,809 shares of company stock valued at $89,809,385 in the last 90 days. Insiders own 7.30% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. raised its position in Spark Therapeutics by 23.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Spark Therapeutics in the 2nd quarter valued at $143,000. Teacher Retirement System of Texas purchased a new stake in Spark Therapeutics in the 3rd quarter valued at $225,000. Prudential Financial Inc. purchased a new stake in Spark Therapeutics in the 3rd quarter valued at $239,000. Finally, Commonwealth Equity Services Inc purchased a new stake in Spark Therapeutics in the 3rd quarter valued at $257,000. Hedge funds and other institutional investors own 94.94% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/15/1-74-earnings-per-share-expected-for-spark-therapeutics-inc-once-this-quarter.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.